William Blair Weighs in on TransMedics Group, Inc.’s Q2 2024 Earnings (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair lifted their Q2 2024 earnings estimates for TransMedics Group in a research report issued on Tuesday, April 30th. William Blair analyst R. Daniels now expects that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of ($0.11). The consensus estimate for TransMedics Group’s current full-year earnings is ($0.14) per share. William Blair also issued estimates for TransMedics Group’s Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at $0.23 EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.28 EPS.

Several other brokerages have also commented on TMDX. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday. TD Cowen upped their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday. Oppenheimer lifted their price objective on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley increased their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $120.00 price target (up from $95.00) on shares of TransMedics Group in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

TransMedics Group Trading Up 2.9 %

Shares of TMDX stock opened at $127.99 on Friday. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $129.66. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock has a 50 day simple moving average of $85.54 and a 200-day simple moving average of $76.85.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. TransMedics Group’s revenue for the quarter was up 132.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.08) EPS.

Institutional Investors Weigh In On TransMedics Group

Institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its holdings in shares of TransMedics Group by 42.5% in the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after acquiring an additional 1,407,171 shares during the last quarter. Vanguard Group Inc. lifted its stake in TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after purchasing an additional 50,673 shares in the last quarter. Eventide Asset Management LLC boosted its position in shares of TransMedics Group by 7.4% during the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock worth $78,475,000 after buying an additional 68,884 shares during the period. Sandhill Capital Partners LLC grew its stake in shares of TransMedics Group by 4.2% in the fourth quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after buying an additional 30,591 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after buying an additional 363,012 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TransMedics Group

In related news, Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director James R. Tobin sold 15,040 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the transaction, the director now directly owns 205,171 shares in the company, valued at $21,836,349.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 7,157 shares of TransMedics Group stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the sale, the director now owns 8,350 shares in the company, valued at approximately $721,273. The disclosure for this sale can be found here. Insiders have sold a total of 236,378 shares of company stock worth $23,633,449 in the last quarter. Company insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.